SEC Company Response from TuHURA Biosciences, (HURA) — Feb 19, 2019

TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: Feb. 19, 2019 · CIK: 0001498382 · Accession: 0001213900-19-002777

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-229020

Date

Feb. 19, 2019

Author

Chief

Form

CORRESP

Company

TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)

Letter

DelMar Pharmaceuticals, Inc.

Suite 720-999 West Broadway

Vancouver, British Columbia, Canada V5Z 1K5

February 19, 2019

VIA EDGAR SUBMISSION

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, NE

Washington, D.C. 20549

Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS

DelMar Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-229020

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement to Tuesday, February 19, 2019, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

Thank you for your assistance. If you should have any questions, please contact Steven M. Skolnick of Lowenstein Sandler LLP, counsel to the Registrant, at (212) 262-6700.

Very
truly yours,
DelMar
Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

DelMar
Pharmaceuticals, Inc.

Suite
720-999 West Broadway

Vancouver,
British Columbia, Canada V5Z 1K5

February
19, 2019

VIA
EDGAR SUBMISSION

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
D.C. 20549

 Re: REQUEST
FOR ACCELERATION OF EFFECTIVENESS

    DelMar
Pharmaceuticals, Inc.

    Registration
Statement on Form S-3

    File
No. 333-229020

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced
registration statement to Tuesday, February 19, 2019, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

Thank
you for your assistance. If you should have any questions, please contact Steven M. Skolnick of Lowenstein Sandler LLP, counsel
to the Registrant, at (212) 262-6700.

    Very
    truly yours,

    DelMar
    Pharmaceuticals, Inc.

    By:
    /s/
    Saiid Zarrabian

    Name:
    Saiid
    Zarrabian

    Title:
    Chief
    Executive Officer

SecProbe.io